AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Young women fare worse in physical, psychosocial function after cancer diagnosis.

Women's Health Weekly

| June 03, 2004 | COPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2004 JUN 3 - (NewsRx.com & NewsRx.net) -- Young women may fare worse than older females in terms of physical and psychosocial function after being diagnosed with breast cancer, say Harvard University researchers.

"A total of 122,969 women from the Nurses' Health Study (NHS) and NHS 2, ages 29 to 71 years, who responded to pre- and postfunctional status assessments were included; 1,082 women were diagnosed with breast cancer between 1992 and 1997. Functional status was measured using the Medical Outcomes Study Short Form 36 (SF-36). Mean change in health-related quality of life (HRQoL) scores was computed across categories representing the combination of incident breast cancer (yes or no) and age at diagnosis (less than or equal to 40, 41 to 64, or 65+ years)," Candyce Kroenke and colleagues said.

"Compared with women less than or equal to 40 years without breast cancer, women with breast cancer experienced significant functional declines. Young (age less than or equal to 40) women who developed breast cancer experienced the largest relative declines in HRQoL (as compared with middle-aged and elderly women) in multiple domains including physical roles (-18.8 vs. -11.5 and -7.5 points, respectively); bodily pain (-9.0 vs. -2.7 and -2.7 points); social functioning (-11.3 vs. -4.3 ...

Related articles from newspapers, magazines, journals, and more
Vysis' HER-2 DNA Probe Test for Breast Cancer Cited in Journal of Clinical...
Press release article from: PR Newswire December 12, 2000 700+ words
...of the Journal of Clinical Oncology highlights the assessment...HER-2 status in breast cancer using Vysis' proprietary...Alteration in Human Breast Cancer: A direct Comparison...HER-2 status in breast cancer," stated Dennis...
New Data Presented at ASCO Show Dose-Dense Chemotherapy Including ELLENCE...
News wire article from: AScribe Medicine News Service June 5, 2004 700+ words
...the American Society of Clinical Oncology suggest that a chemotherapy...significantly improve survival in breast cancer patients at highest risk...adjuvant therapy in high-risk breast cancer patients significantly improves...advancement in the treatment of breast cancer ...
PRESS RELEASE: Vysis' HER-2 DNA probe test for breast cancer cited in Journal...
News wire article from: Chemical Business Newsbase December 19, 2000 700+ words
...of the Journal of Clinical Oncology highlights the assessment...HER-2 status in breast cancer using Vysis' proprietary...Alteration in Human Breast Cancer: A direct Comparison...HER-2 status in breast cancer. Vysis Inc, Downers...
The Use of Taxotere(R) in Treating Breast Cancer Highlighted at American...
Press release article from: PR Newswire June 2, 2003 700+ words
...early and advanced breast cancer according to numerous...American Society of Clinical Oncology (ASCO). Among the...women with early stage breast cancer before (neoadjuvant...operable, invasive breast cancer showed a 21 percent...
First Clinical Guidelines For Breast Cancer Risk Reduction Published in Journal...
Press release article from: PR Newswire June 11, 1999 700+ words
...Society of Clinical Oncology confirms Nolvadex...reduction of breast cancer risk in high...Society of Clinical Oncology's (ASCO...Assessment on Breast Cancer Risk Reduction...Journal of Clinical Oncology, clearly...
Femara(R) Demonstrated Early Survival Advantage Over Tamoxifen in Advanced...
Press release article from: PR Newswire May 28, 2003 700+ words
...therapy in advanced breast cancer demonstrated that...advanced or metastatic breast cancer. The study was published...of the Journal of Clinical Oncology (JCO). The data...patients with advanced breast cancer. They show that...
Study Highlights Importance of LongTerm Survival, Side Effect Considerations in...
News wire article from: Europe Intelligence Wire July 28, 2004 700+ words
...cancer centers conducting breast cancer research in France. A comprehensive...issue of The Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology. About Breast Cancer and ELLENCE Breast cancer...
Femara demonstrated early survival advantage over tamoxifen in advanced breast...
News wire article from: Asia Africa Intelligence Wire May 28, 2003 700+ words
...therapy in advanced breast cancer demonstrated that...advanced or metastatic breast cancer. The study was published...of the Journal of Clinical Oncology (JCO). The data...patients with advanced breast cancer. They show that...
Spectrum Pharmaceuticals to Present Phase 2 Data on Ortataxel in Breast Cancer...
Press release article from: Business Wire May 19, 2008 700+ words
...Advanced or Metastatic Breast Cancer * Ortataxel Has Been...American Society of Clinical Oncology (ASCO) Annual Meeting...study in resistant breast cancer patients will be presented...Taxane-Resistant Breast Cancer" is available now...
The use of Taxotere in treating breast cancer highlighted at American Society...
News wire article from: Asia Africa Intelligence Wire June 2, 2003 700+ words
...early and advanced breast cancer according to numerous...American Society of Clinical Oncology (ASCO). Among the...women with early stage breast cancer before or after surgery...operable, invasive breast cancer showed a 21% reduction...
For more facts and information, see all results

Source: HighBeam Research, Young women fare worse in physical, psychosocial function after...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA